BTIG Maintains Buy on CareDx, Raises Price Target to $60
BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $45 to $60.
Read original at benzingaStocks · News reference
CareDx Finalizes Medicare Local Coverage Determination Procedure Regarding Molecular Testing For Solid Organ Allograft Rejection
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD)
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 16, 2026, 12:35 PM
- Checked
- Jul 16, 2026, 12:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday
Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 results, other stocks also recording gains.
Read original at benzingaWhy CareDx Stock Jumped Today
CareDx stock surged 14.72% after the precision medicine diagnostics company raised its full-year revenue and earnings forecasts. The company reported adjusted net income more than tripled to $20 million ($0.37 per share), significantly exceeding Wall Street estimates of $0.23 per share. Growth was driven by increased demand for non-invasive transplant monitoring tests, favorable reimbursement dynamics, and CMS coverage affirmation for kidney, heart, and lung transplant surveillance testing.
Read original at the-motley-foolCareDx shares are trading higher after the company reported better-than-expected Q2 financial results. Also, the company raised its FY2026 sales guidance above estimates.
Read original at benzinga